GLP-1 receptor agonist and composition and use thereof

A compound of Formula II:

• or a pharmaceutically acceptable salt or stereoisomer thereof,
• wherein:
• represents a single or double bond;
• W is selected from the group consisting of O, N, and NH;
• X3 and X4 are independently selected from the group consisting of CH, N, and C;
• Y1 is selected from the group consisting of CH and N;
• Y2 is selected from the group consisting of CH, N, and C;
• Y3 is selected from the group consisting of CH, N, and C;
• R1 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy;
• R2 is Rz—C1-3 alkylene-;
• R4 is independently selected from the group consisting of hydrogen, halogen, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, cyano, hydroxy, amino, amido, sulfonyl, and sulfonamido;
• R5 is independently selected from the group consisting of hydrogen, halogen, hydroxy, CN, C1-3 alkyl, C1-3 alkoxy, and C3-6 cycloalkyl;
• R0 is independently selected from the group consisting of hydrogen, hydroxyl, and halogen;
• n is 0, 1, 2, 3, or 4;
• m is 0, 1, or 2;
• p is 0, 1, 2, or 3;
• q is 0, 1, 2, 3, or 4;
• when m is not 0 and p is not 0, any R4 and any R5 may, together with the ring atoms of ring B and ring C therebetween, form a 5- to 8-membered ring, wherein the 5- to 8-membered ring may optionally be substituted 1 to 3 times by C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, halogen, cyano, oxo, or C1-3 alkoxy, if the valence permits;
• Rz is selected from the group consisting of C3-6 cycloalkyl and 3- to 6-membered heterocyclyl, wherein Rz may be optionally substituted 1 to 3 times by C1-3 alkyl, C1-3 haloalkyl, cyano-C1-3 alkyl, halogen, cyano, oxo, C1-3 alkoxy, or 3- to 6-membered heterocyclyl.